Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
Cancer Lett
    September 2022
  1. LIU X, Zhang G, Yu T, He J, et al
    Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
    Cancer Lett. 2022;543:215781.
    >> Share

    July 2022
  2. DU Z, Feng Y, Zhang H, Liu J, et al
    Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation.
    Cancer Lett. 2022 Jul 31:215841. doi: 10.1016/j.canlet.2022.215841.
    >> Share

    May 2022
  3. YUE P, Zhu Y, Brotherton-Pleiss C, Fu W, et al
    Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Cancer Lett. 2022;534:215613.
    >> Share

  4. LAW ME, Yaaghubi E, Ghilardi AF, Davis BJ, et al
    Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
    Cancer Lett. 2022;534:215604.
    >> Share

  5. GOBEL A, Riffel RM, Hofbauer LC, Rachner TD, et al
    The mevalonate pathway in breast cancer biology.
    Cancer Lett. 2022 May 28:215761. doi: 10.1016/j.canlet.2022.215761.
    >> Share

  6. LAURIN KM, Coutu-Beaudry K, Salazar A, Meribout N, et al
    Low expression of PGC-1beta and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1.
    Cancer Lett. 2022 May 17:215738. doi: 10.1016/j.canlet.2022.215738.
    >> Share

  7. SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al
    Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases.
    Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726.
    CNTF axis to promote progression of brain metastases.&body=SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al. Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases. Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726." ALT="Email" TITLE="Email"> --> >> Share

  8. TIMILSINA S, Rajamanickam S, Rao AD, Subbarayalu P, et al
    The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
    Cancer Lett. 2022 May 11:215717. doi: 10.1016/j.canlet.2022.215717.
    >> Share

    April 2022
  9. MA S, Zhang J, Guo Q, Cao C, et al
    Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
    Cancer Lett. 2022;530:29-44.
    >> Share

    March 2022
  10. YU S, Li W, Tang L, Fan X, et al
    Depression in breast cancer patients: Immunopathogenesis and immunotherapy.
    Cancer Lett. 2022;536:215648.
    >> Share

  11. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
    Cancer Lett. 2022 Mar 9:215629. doi: 10.1016/j.canlet.2022.215629.
    >> Share

  12. DU G, Sun J, Li Z, Zhang Q, et al
    A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
    Cancer Lett. 2022 Mar 5:215618. doi: 10.1016/j.canlet.2022.215618.
    >> Share

  13. LYU X, Zhang Q, Fares HM, Wang Y, et al
    Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Cancer Lett. 2022;534:215616.
    >> Share

    February 2022
  14. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    >> Share

    January 2022
  15. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    >> Share

  16. CHAIB M, Sipe LM, Yarbro JR, Bohm MS, et al
    PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer.
    Cancer Lett. 2022 Jan 21. pii: S0304-3835(22)00025.
    >> Share

  17. MISHRA A, Hourigan D, Lindsay AJ
    Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
    Cancer Lett. 2022;529:153-167.
    >> Share

  18. HOUBEN R, Hesbacher S, Sarma B, Schulte C, et al
    Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
    Cancer Lett. 2022;524:259-267.
    >> Share

  19. PENG Y, Chen Z, He Y, Li P, et al
    Non-muscle myosin II isoforms orchestrate substrate stiffness sensing to promote cancer cell contractility and migration.
    Cancer Lett. 2022;524:245-258.
    >> Share

  20. ZOU Y, Liu B, Li L, Yin Q, et al
    IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.
    Cancer Lett. 2022;524:121-130.
    >> Share

    December 2021
  21. WANG Z, Wang F, Ding XY, Li TE, et al
    Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Cancer Lett. 2021 Dec 17. pii: S0304-3835(21)00632.
    >> Share

  22. CHAI C, Wu HH, Abuetabh Y, Sergi C, et al
    Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Cancer Lett. 2021;527:41-48.
    >> Share

  23. TANG W, Xia M, Liao Y, Fang Y, et al
    Exosomes in triple negative breast cancer: From bench to bedside.
    Cancer Lett. 2021;527:1-9.
    >> Share

    November 2021
  24. CHADELLE L, Liu J, Choesmel-Cadamuro V, Karginov AV, et al
    PKCtheta-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.
    Cancer Lett. 2021 Nov 23. pii: S0304-3835(21)00599.
    >> Share

  25. KHUMUKCHAM SS, Penugurti V, Soni A, Uppala V, et al
    A reciprocal feedback loop between HIF-1alpha and HPIP controls phenotypic plasticity in breast cancer cells.
    Cancer Lett. 2021 Nov 9. pii: S0304-3835(21)00568.
    >> Share

  26. ALRAOUJI NN, Hendrayani SF, Ghebeh H, Al-Mohanna FH, et al
    Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the beta-catenin pathway.
    Cancer Lett. 2021;520:374-384.
    >> Share

  27. LEE O, Bosland MC, Wang M, Shidfar A, et al
    Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Cancer Lett. 2021;520:255-266.
    >> Share

    October 2021
  28. WANG SF, Chang YL, Tony Tzeng YD, Wu CL, et al
    Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00504.
    >> Share

  29. ALSHEIKH HAM, Metge BJ, Ha CM, Hinshaw DC, et al
    Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
    Cancer Lett. 2021;517:24-34.
    >> Share

    September 2021
  30. XIA M, Zu X, Chen Z, Wen G, et al
    Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
    Cancer Lett. 2021 Sep 30. pii: S0304-3835(21)00499.
    >> Share

  31. LI C, Qiu S, Jin K, Zheng X, et al
    Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
    Cancer Lett. 2021;523:43-56.
    >> Share

  32. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
    SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2021;522:211-224.
    >> Share

  33. BHATTARAI PY, Kim G, Poudel M, Lim SC, et al
    METTL3 induces PLX4032 resistance in melanoma by promoting m(6)A-dependent EGFR translation.
    Cancer Lett. 2021;522:44-56.
    >> Share

    August 2021
  34. ZHANG M, Liu J, Liu G, Xing Z, et al
    Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
    Cancer Lett. 2021 Aug 10. pii: S0304-3835(21)00394.
    >> Share

  35. NYATI KK, Hashimoto S, Singh SK, Tekguc M, et al
    The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
    Cancer Lett. 2021;520:295-306.
    >> Share

  36. ZHU Y, Zhang H, Han X, Wang Z, et al
    STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.
    Cancer Lett. 2021 Aug 1. pii: S0304-3835(21)00380.
    >> Share

    July 2021
  37. ZHANG X, Hu Z, Wang X, Li L, et al
    ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
    Cancer Lett. 2021 Jul 26. pii: S0304-3835(21)00360.
    >> Share

  38. MCGARRY DJ, Armstrong G, Castino G, Mason S, et al
    MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours.
    Cancer Lett. 2021 Jul 24. pii: S0304-3835(21)00371.
    >> Share

  39. PENUGURTI V, Khumukcham SS, Padala C, Dwivedi A, et al
    HPIP protooncogene differentially regulates metabolic adaptation and cell fate in breast cancer cells under glucose stress via AMPK and RNF2 dependent pathways.
    Cancer Lett. 2021;518:243-255.
    >> Share

  40. PETRI BJ, Piell KM, South Whitt GC, Wilt AE, et al
    HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
    Cancer Lett. 2021;518:152-168.
    >> Share

  41. XU X, Li N, Wang Y, Yu J, et al
    Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.
    Cancer Lett. 2021;519:150-160.
    >> Share

  42. MININI M, Senni A, He X, Proietti S, et al
    miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting.
    Cancer Lett. 2021 Jul 3. pii: S0304-3835(21)00326.
    >> Share

    June 2021
  43. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    >> Share

  44. SANG X, Li L, Rui C, Liu Y, et al
    Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
    Cancer Lett. 2021;518:82-93.
    >> Share

  45. SINGHAL SS, Srivastava S, Mirzapoiazova T, Horne D, et al
    Targeting the mercapturic acid pathway for the treatment of melanoma.
    Cancer Lett. 2021;518:10-22.
    >> Share

  46. REGUA AT, Arrigo A, Doheny D, Wong GL, et al
    Transgenic mouse models of breast cancer.
    Cancer Lett. 2021;516:73-83.
    >> Share

    May 2021
  47. DIMITRAKOPOULOS FI, Kottorou A, Tzezou A
    Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
    Cancer Lett. 2021 May 30. pii: S0304-3835(21)00254.
    >> Share

  48. WANG H, Shi Y, Chen CH, Wen Y, et al
    KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.
    Cancer Lett. 2021;515:49-62.
    >> Share

  49. LI X, Wang H, Yang X, Wang X, et al
    GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
    Cancer Lett. 2021 May 20. pii: S0304-3835(21)00194.
    >> Share

  50. PROVANCE OK, Geanes ES, Lui AJ, Roy A, et al
    Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
    Cancer Lett. 2021;514:12-29.
    >> Share

  51. LIGORIO F, Pellegrini I, Castagnoli L, Vingiani A, et al
    Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
    Cancer Lett. 2021 May 4. pii: S0304-3835(21)00189.
    >> Share

  52. WANG M, Dai M, Wang D, Tang T, et al
    The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway.
    Cancer Lett. 2021 May 2. pii: S0304-3835(21)00191.
    >> Share

    April 2021
  53. COPPO R, Orso F, Virga F, Dalmasso A, et al
    ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.
    Cancer Lett. 2021;510:13-23.
    >> Share

  54. VENKATESH J, Wasson MD, Brown JM, Fernando W, et al
    LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
    Cancer Lett. 2021 Apr 10. pii: S0304-3835(21)00156.
    >> Share

  55. GONCALVES RM, Delgobo M, Agnes JP, das Neves RN, et al
    COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
    Cancer Lett. 2021;502:44-57.
    >> Share

  56. MCALEESE CE, Choudhury C, Butcher NJ, Minchin RF, et al
    Hypoxia-mediated drug resistance in breast cancers.
    Cancer Lett. 2021;502:189-199.
    >> Share

  57. WANG CJ, Li D, Danielson JA, Zhang EH, et al
    Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Cancer Lett. 2021 Apr 1. pii: S0304-3835(21)00149.
    >> Share

    March 2021
  58. KAUL K, Misri S, Ramaswamy B, Ganju RK, et al
    Contribution of the tumor and obese microenvironment to triple negative breast cancer.
    Cancer Lett. 2021 Mar 30. pii: S0304-3835(21)00141.
    >> Share

  59. GRILLO E, Corsini M, Ravelli C, Zammataro L, et al
    Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
    Cancer Lett. 2021;507:80-88.
    >> Share

  60. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    >> Share

    February 2021
  61. SONG D, He H, Sinha I, Hases L, et al
    Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    Cancer Lett. 2021 Feb 27. pii: S0304-3835(21)00092.
    >> Share

  62. HUANG M, Zhou Y, Duan D, Yang C, et al
    Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib.
    Cancer Lett. 2021 Feb 16. pii: S0304-3835(21)00074.
    >> Share

  63. ZHANG Y, Fan Y, Jing X, Zhao L, et al
    OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression.
    Cancer Lett. 2021 Feb 12. pii: S0304-3835(21)00068.
    >> Share

  64. KUMAR S, Prajapati KS, Singh AK, Kushwaha PP, et al
    Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer.
    Cancer Lett. 2021 Feb 5. pii: S0304-3835(20)30637.
    >> Share

  65. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    >> Share

    January 2021
  66. VAN DE VELDE M, Ebroin M, Durre T, Joiret M, et al
    Tumor exposed-lymphatic endothelial cells promote primary tumor growth via IL6.
    Cancer Lett. 2021;497:154-164.
    >> Share

  67. BOURN JR, Ruiz-Torres SJ, Hunt BG, Benight NM, et al
    Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
    Cancer Lett. 2021 Jan 25. pii: S0304-3835(21)00035.
    >> Share

  68. CHENG R, Wang Z, Kong X, Qi L, et al
    Factors associated with chemotherapy benefit in breast cancer patients with midrange oncotype DX breast recurrence scores.
    Cancer Lett. 2021 Jan 21. pii: S0304-3835(21)00032.
    >> Share

  69. LI X, Chen M, Lu W, Tang J, et al
    Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
    Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
    >> Share

  70. YANG Y, Li S, Li B, Li Y, et al
    FBXL10 promotes ERRalpha protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERRalpha.
    Cancer Lett. 2021 Jan 12. pii: S0304-3835(21)00023.
    >> Share

  71. WU PK, Hong SK, Park JI
    Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf(V600E) melanoma cells.
    Cancer Lett. 2021 Jan 10. pii: S0304-3835(21)00007.
    >> Share

    December 2020
  72. BOTELHO DE SOUZA LE, Ferreira FU, Thome CH, Brand H, et al
    Human and mouse melanoma cells recapitulate an EMT-like program in response to mesenchymal stromal cells secretome.
    Cancer Lett. 2020 Dec 28. pii: S0304-3835(20)30701.
    >> Share

  73. SHI Y, Zhang Y, Ran F, Liu J, et al
    Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Cancer Lett. 2020;495:53-65.
    >> Share

  74. ZHANG T, Wu B, Akakuru OU, Yao C, et al
    Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer.
    Cancer Lett. 2020;500:41-50.
    >> Share

  75. MAVINGIRE N, Campbell P, Wooten J, Aja J, et al
    Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes.
    Cancer Lett. 2020 Dec 9. pii: S0304-3835(20)30664.
    >> Share

  76. KIM SJ, Saeidi S, Cho NC, Kim SH, et al
    Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression: Implications for breast cancer progression.
    Cancer Lett. 2020 Dec 2. pii: S0304-3835(20)30645.
    >> Share

    November 2020
  77. HARTMAN ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, et al
    BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30635.
    >> Share

  78. KIM G, Bhattarai PY, Lim SC, Kim JY, et al
    PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation.
    Cancer Lett. 2020 Nov 27. pii: S0304-3835(20)30631.
    >> Share

  79. WANG YY, Hung AC, Lo S, Yuan SF, et al
    Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
    Cancer Lett. 2020 Nov 2. pii: S0304-3835(20)30580.
    >> Share

  80. ZENG J, Li G, Xia Y, Wang F, et al
    miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.
    Cancer Lett. 2020;492:185-196.
    >> Share

    October 2020
  81. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    >> Share

  82. BAI X, Ni J, Beretov J, Graham P, et al
    Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Cancer Lett. 2020;497:100-111.
    >> Share

  83. ZHANG N, Sun P, Xu Y, Li H, et al
    The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERalpha to inhibit the growth of breast cancer induced by oestrogen.
    Cancer Lett. 2020 Oct 15. pii: S0304-3835(20)30545.
    >> Share

  84. DUTTA I, Dieters-Castator D, Papatzimas JW, Medina A, et al
    ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to gammadelta T cell immunotherapy.
    Cancer Lett. 2020 Oct 9. pii: S0304-3835(20)30535.
    >> Share

    September 2020
  85. OH JH, Lee JY, Kim KH, Kim CY, et al
    Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Cancer Lett. 2020;495:145-155.
    >> Share

  86. LIU S, Zhang J, Fang S, Su X, et al
    Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
    Cancer Lett. 2020 Sep 15. pii: S0304-3835(20)30475.
    >> Share

  87. LI Y, Zhang H, Li Q, Zou P, et al
    CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
    Cancer Lett. 2020 Sep 14. pii: S0304-3835(20)30473.
    >> Share

  88. RONG Y, Huang LX, Yi KZ, Chen H, et al
    Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
    Cancer Lett. 2020 Sep 3. pii: S0304-3835(20)30455.
    >> Share

    August 2020
  89. MA L, Wang L, Nelson AT, Han C, et al
    27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
    Cancer Lett. 2020 Aug 27. pii: S0304-3835(20)30435.
    >> Share

  90. LOBO YA, Bonazza C, Batista FP, Castro RA, et al
    EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines.
    Cancer Lett. 2020 Aug 22. pii: S0304-3835(20)30431.
    >> Share

  91. ZHAO CC, Zhan MN, Liu WT, Jiao Y, et al
    Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
    Cancer Lett. 2020 Aug 20. pii: S0304-3835(20)30419.
    >> Share

  92. XIE Y, Hu Y, Zhou N, Yao C, et al
    CAR T-cell therapy for triple-negative breast cancer: Where we are.
    Cancer Lett. 2020 Aug 11. pii: S0304-3835(20)30400.
    >> Share

  93. TEOH ST, Ogrodzinski MP, Lunt SY
    UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30388.
    >> Share

  94. REN J, Wang Y, Ware T, Iaria J, et al
    Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30398.
    >> Share

    July 2020
  95. NIETO-JIMENEZ C, Galan-Moya EM, Corrales-Sanchez V, Del Mar Noblejas-Lopez M, et al
    Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Cancer Lett. 2020 Jul 28. pii: S0304-3835(20)30350.
    >> Share

  96. RONG D, Wang C, Zhang X, Wei Y, et al
    A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
    Cancer Lett. 2020 Jul 27. pii: S0304-3835(20)30355.
    >> Share

  97. HWANG HJ, Lee YR, Kang D, Lee HC, et al
    Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells.
    Cancer Lett. 2020 Jul 10. pii: S0304-3835(20)30349.
    >> Share

    June 2020
  98. HUANG B, Yip WK, Wei N, Luo KQ, et al
    Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
    Cancer Lett. 2020 Jun 22. pii: S0304-3835(20)30340.
    >> Share

  99. AGGARWAL V, Miranda O, Johnston PA, Sant S, et al
    Three dimensional engineered models to study hypoxia biology in breast cancer.
    Cancer Lett. 2020 Jun 19. pii: S0304-3835(20)30292.
    >> Share

  100. BABAK MV, Zalutsky MR, Balyasnikova IV
    Heterogeneity and vascular permeability of breast cancer brain metastases.
    Cancer Lett. 2020 Jun 16. pii: S0304-3835(20)30342.
    >> Share

  101. WANG B, Mao JH, Wang BY, Wang LX, et al
    Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-kappaB signaling pathway.
    Cancer Lett. 2020 Jun 9. pii: S0304-3835(20)30300.
    >> Share

    May 2020
  102. FERRER A, Roser CT, El-Far MH, Savanur VH, et al
    Hypoxia-mediated changes in bone marrow microenvironment in breast cancer dormancy.
    Cancer Lett. 2020 May 29. pii: S0304-3835(20)30288.
    >> Share

  103. BISHOP RT, Marino S, Carrasco G, Li B, et al
    Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
    Cancer Lett. 2020 May 28. pii: S0304-3835(20)30282.
    >> Share

  104. BARUA D, Gupta A, Gupta S
    Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges.
    Cancer Lett. 2020 May 21. pii: S0304-3835(20)30283.
    >> Share

  105. HE Z, Khatib AM, Creemers JWM
    Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
    Cancer Lett. 2020 May 7. pii: S0304-3835(20)30229.
    >> Share

    April 2020
  106. SZOOR A, Toth G, Zsebik B, Szabo V, et al
    Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
    Cancer Lett. 2020 Apr 11. pii: S0304-3835(20)30185.
    >> Share

  107. ULASOV I, Borovjagin A, Fares J, Yakushov S, et al
    MicroRNA 345 (miR345) regulates KISS1-E-cadherin functional interaction in breast cancer brain metastases.
    Cancer Lett. 2020;481:24-31.
    >> Share

    March 2020
  108. ANG L, Guo L, Wang J, Huang J, et al
    Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
    Cancer Lett. 2020 Mar 18. pii: S0304-3835(20)30131.
    >> Share

    January 2020
  109. DING J, Yao Y, Huang G, Wang X, et al
    Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30046.
    >> Share

  110. GOH CY, Wyse C, Ho M, O'Beirne E, et al
    Exosomes in Triple Negative Breast Cancer: Garbage Disposals or Trojan Horses?
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30668.
    >> Share

  111. BAROK M, Le Joncour V, Martins A, Isola J, et al
    ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30659.
    >> Share

    November 2019
  112. PAN T, Zhou D, Shi Z, Qiu Y, et al
    Centromere Protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2.
    Cancer Lett. 2019 Nov 6. pii: S0304-3835(19)30558.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016